Amicus Therapeutics’ Control for Diseases

Home / Amicus Therapeutics’ Control for Diseases

Amicus Therapeutics is an American-based biopharmaceutical firm based in Cranbury, New Jersey. The company was established on February 4, 2002. Amicus Therapeutics’ outstanding operation became known in 2007 when it went viral. During that year, the organization was placed under the umbrella of NASDAQ in the FOLD trading symbol which helped it go public. Before the firm’s IPO, Amicus sourced its capital from various venture capital enterprises including Canaan Partners, Radius Ventures, and the New Enterprise Associates. The key personalities of Amicus Therapeutics are John Crowley, William Baird, and Bradley Campbell.

 

The organization’s therapeutic focus is on orphan and rare ailments, specifically the lysosomal storage diseases. Amicus’ product augmentation is based on a therapy termed as CHART, Chaperone-Advanced Replacement Therapy. The therapy’s specialty is in the development of replacement of enzymes for patients. Under the leadership of the three key individuals, Amicus Therapeutics was noted as possessing the hugest portfolio of tiny molecule pharmacological chaperones in the pharmaceutical sector. Migaslat is the company’s client for the curing of Fabris disorder by stabilizing endogenous mutant alpha-galactosidase.

 

From 2010 to 2013, Amicus Therapeutics partnered with JRC Pharmaceuticals and GlaxoSmithKline to research alpha-galactosidase (WeeklyOpinion). Working with other companies was of importance to Amicus. In 2008, it experienced an expansion in its operations from Amicus’ single New Jersey site to a grown site in San Diego. Also, Amicus Therapeutics is funded by different organizations including The Michael J Foundation, which gave Amicus US$500,000 to support its research. Over the years, Amicus Therapeutics possessed Callidus Biopharma thus obtaining property necessary for replacement of enzyme for Pompe disease treatment.

 

Amicus Therapeutics’ activities and services are done with passion. The company leverages biology with technology in the development of their treatment products. Amicus program of biology is ATB200/AT2221. The biology program is exclusive as it is engineered to specifically cure Pompe ailment using enzyme replacement therapy combined with a pharmacological chaperone. The governance of the company is stunning. It consists of medical experts who provide their knowledge in the business’s operations. As of 2013, Amicus Therapeutics had 92 trustworthy employees (https://www.google.com/finance?cid=706165). Over time, the company’s staff has grown to competent and skilled personnel.